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Abstract: Aim: To systematically review the impact of the Two-Week Rule in increasing the pick-up rate of colorectal 
cancers and Upper Gastrointestinal (GI) cancers in the NHS. 
Materials and Methods: Data were combined for meta-analyses to determine (1) the Two-Week Rule pick-up rate for each 
cancer type and (2) the proportion of patients referred using the Two-Week Rule. Overall results were given as weighted 
averages.  
Results: There were 20 articles and 27 peer-reviewed abstracts included in this review. Colorectal Cancer: Only 9.5% of 
patients referred by the Two-Week Rule were eventually diagnosed with colorectal cancer (n = 24). When examining the 
referral origin of all colorectal cancer patients diagnosed during the time of 19 studies with this data, 32.2% had been re-
ferred using the Two-Week Rule. Upper GI Cancer: Only 5.5% of patients referred by the Two-Week Rule were eventu-
ally diagnosed with Upper GI cancer (n = 23). When examining the referral origin of all Upper GI cancer patients diag-
nosed during the time of 17 studies with this data, 23.6% had been referred using the Two-Week Rule.  
Conclusion: The Two-Week Rule is not sufficiently effective in diagnosing neither upper GI nor colorectal cancers in pa-
tients presenting to their General Practitioner. 
BACKGROUND  
 The Two-Week Rule (TWR) referral [1] was introduced 
by the UK’s New Labour government in 2000 as one of 
many initiatives tackling the increasing problem of patients 
presenting to their General Practitioner (GP) with symptoms 
indicative of a cancer who, although urgently referred, did 
not get a hospital appointment in sufficient time to signifi-
cantly improve their health outcome. It was hoped that the 
TWR referral route would help to reduce the number of can-
cer-related deaths by 20% in people under the age of 75 
years by 2010, thereby saving approximately 130,000 lives 
[2]. The scheme allowed GPs to “fast-track” these patients to 
shorten the length of time they waited for a diagnosis fol-
lowed by potentially life saving treatment. TWR referrals 
were faxed to the relevant diagnostic unit using a dedicated 
number and an appointment was made for the patient within 
two weeks. Only delays due to patient choice were accept-
able reasons to over-run the two week target.  
 Disease-specific guidelines [3, 4] were published with 
the aim of helping GPs make decisions about when to refer 
people to specialists when they presented with symptoms 
that could have been caused by cancer. This would facilitate 
the appropriate referral of suspected cancer patients using the 
TWR. In the case of gastrointestinal (GI) cancers, the referral 
guidelines applied to upper GI cancers (UGCs) including 
oesophageal and gastric cancer, and colorectal cancers 
(CRCs). 
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 In 2006 we published a systematic literature review, re-
porting that the CRC pick-up rate for the TWR referral for 
suspected CRC patients was only 10.3% [5]. However, this 
figure was based on a meta-analysis using only eight peer-
reviewed articles published at the time. We now offer a more 
comprehensive review by updating the original search with 
recent evidence and by altering the inclusion criteria to in-
clude eligible peer-reviewed abstracts into the meta-analysis. 
We have also extended our updated review to include UGCs 
for the first time. 
METHODS 
 A literature search was performed using Pubmed and the 
Cochrane Library employing a text search for peer-reviewed 
research articles. The search terms used were “colorectal”, 
“CRC”, “upper gastroint*”, “upper GI”, “gastrointestinal”, 
“oesophageal” and “gastric” in combination with “urgent 
referral*”, “two week*”, “2-week*”, “fourteen day*” and 
“fast track”. In addition to this, all peer-reviewed abstracts 
presented at the internationally renowned British Society of 
Gastroenterology (BSG) conferences since published in Gut 
journal supplements since 2000 were hand-searched to locate 
suitable abstracts for inclusion in the meta-analyses. The 
lead author of this review did all literature searching and 
article assessments using pre-defined search and inclusion 
criteria agreed by all authors. 
 Only peer-reviewed studies commenting on the effec-
tiveness of the TWR in diagnosing GI cancers were selected. 
Studies performed in non-NHS organisations were excluded. 
Studies were also excluded if they had no comparable data to 
contribute to the meta-analysis. Where a research article also 
had a peer-reviewed abstract by the same author on the same 
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topic, the research article was used in the review and the 
abstract was excluded.  
 Data describing the TWR GI cancer pick-up rate and the 
proportion of GI cancer patients diagnosed using the TWR 
identified were extracted and split according to cancer type 
(UGC or CRC). Data extracted were actual values. Data 
were extracted into the following four outcomes for analysis: 
(1) N
o
 TWR referrals received; (2) N
o
 cancers diagnosed 
from the TWR referrals; (3) Total N
o
 cancers diagnosed dur-
ing the study period (irrespective of referral route) and (4) 
the % of all cancers diagnosed that were referred by the 
TWR. Outcomes 1 and 2 are used to calculate the cancer 
pick-up rate for each study (%) by each study author. Many 
go on to compare the number of TWR-referred cancers with 
the total number of cancers diagnosed using outcomes 2 and 
3 to calculate outcome 4. Where one of the outcomes was 
not reported in the article but it could be calculated using the 
other three values, the authors of this article did that calcula-
tion and used that figure for analysis. All studies with com-
parable datasets were combined to give overall results for 
both cancer types, given as weighted averages. 
 We further split the articles retrieved according to two 
time periods: those conducted between Jan 2000 and Dec 
2002 (Group 1) and those conducted between Jan 2003 and 
Dec 2008 (Group 2) to determine whether GI cancer pick-up 
rates had improved over time. Any studies overlapping these 
time periods were allocated into the group where the major-
ity of the study had taken place. Those studies with no start 
and end dates reported were allocated into a time period 
based on their publication date whereby anything published 
before 2003 was automatically included in Group 1. 
RESULTS  
 After critically appraising all articles and abstracts found 
in the literature search, there were 20 published research 
articles and 27 peer-reviewed abstracts with comparable data 
reporting on the effect of the TWR in NHS diagnostic serv-
ices for GI cancers, of which two reported on both upper GI 
and colorectal cancers [6, 7]. Tables 1 & 2 show all raw data 
collected for this study split according to cancer type: CRC 
data (Table 1) and UGC data (Table 2). 
Colorectal Cancers 
 The 24 CRC studies used showed that of the 11304 pa-
tients with a suspected CRC referred by their GP using the 
TWR, only 1070 (9.5%) were subsequently diagnosed with 
CRC. When we split the data according to the period when 
the studies were conducted, we found that for the 14 Group 1 
CRC studies (2000-02), only 633 (11.1%) of 5654 patients 
referred using the TWR were diagnosed with CRC. How-
ever, the 10 Group 2 CRC studies (2003-08) reported that 
only 437 (7.7%) of 5650 patients referred using the TWR 
were diagnosed with CRC.  
 When determining the referral route of all CRC patients 
diagnosed during the time of the 18 studies reporting this 
data, we found that only 1116 of the 3461 (32.2%) CRC pa-
tients diagnosed during the study periods were referred by 
GPs using the TWR. When we examined the data split ac-
cording to time period, we found that 560 of 1782 (31.4%) 
of CRC patients in the nine Group 1 studies had been re-
ferred using the TWR compared with 556 of 1679 (33.1%) 
of nine Group 2 studies. 
Upper GI Cancers 
 The 23 UGC studies identified for this analysis showed 
that for the 7855 patients referred by their GP using the 
TWR for a suspected UGC, only 431 (5.5%) were actually 
diagnosed with one, either oesophageal or gastric. When data 
was split according to time period we found that for the 17 
Group 1 UGC studies, of 6322 patients referred using the 
TWR, only 319 (5%) were diagnosed with a UGC whilst the 
six Group 2 UGC studies, 112 (7.3%) of 1533 patients re-
ferred using the TWR were diagnosed with UGC. 
 When examining the proportion of UGCs diagnosed via 
the TWR, we found that 338 of 1431 (23.6%) patients in 17 
studies had been referred using the TWR. When we split the 
data according to period of study, we found that 171 of 933 
(18.3%) of UGC patients from 10 studies in Group 1 had 
been referred using the TWR, compared with 167 of 498 
(33.5%) of patients with UGCs in seven Group 2 studies. 
DISCUSSION  
 For each type of GI cancer, the overall cancer pick-up 
rate by the TWR was less than 10% (CRC = 9.5% and UGC 
= 5.5%). However, when the data was split according to the 
period when the studies were conducted, we found that 
Group 1 CRC pick-up rates were higher than Group 2 pick-
up rates (11.1% vs 7.7%), whilst Group 1 UGC pick-up rates 
were lower than those of Group 2 (5% vs 7.3%). The overall 
proportion of CRC patients who had been referred via the 
TWR was 32.2% and showed a slight increase when data 
was split according to time period: 31.4% for Group 1 and 
33.1% for Group 2. The overall proportion of UGC patients 
who were referred via the TWR was 23.6%. However, when 
data was split according to time period, we found that only 
18.3% were diagnosed via the TWR in Group 1, compared 
with 33.5% in Group 2. 
 This paper reviewed all relevant peer-reviewed evidence 
from studies reporting on the impact of the TWR on NHS 
services. All datasets have been included from all eligible 
studies for analysis, making this review as comprehensive as 
possible. However, there were a limited amount of peer-
reviewed research articles in this field, with only 20 publica-
tions meeting our inclusion criteria and containing compara-
ble, eligible datasets. For this reason we opted to include 
peer-reviewed abstracts presented at the BSG conferences 
since 2000. There was a wealth of information contained 
within these abstracts, published in annual supplements by 
the Gut journal, but very few ever made it to publication as a 
research article. Wherever they did, for the purpose of this 
review the article was used instead of the abstract. 
 There were three studies, all focussing on UGC patients, 
which did their own “two-stage” studies where they retro-
spectively examined the success of the TWR in diagnosing 
cancer at two distinct time points [44, 48, 51]. Kapoor et al. 
reported a decrease in the UGC pick-up rate for the TWR 
from 3.8% for the period July 2000 - Feb 2002 to 2.9% for 
the period March 2002 - Feb 2003 [44]. However, there were 
relatively similar numbers of TWR referrals in both groups, 
even though the time frame for the second stage study was 
only 12 months compared to the 18 months indicated for the 
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Table 1. Data Extracted for Meta-Analysis Relating to CRC Patients from 27 Studies. Entries are Listed Chronologically  
According to Publication Date. Where Data was not Present in the Article, the Corresponding Box(es) were Greyed Out 
Lead author Ref. Article type 
(1 = article; 
2 = abstract) 
Study start 
date 
(mmm-yy) 
Study end 
date 
(mmm-yy) 
N
o
 TWR 
referrals 
N
o
 cancers 
(%) 
Total N
o
 cancers 
diagnosed during 
the study period 
% cancers 
diagnosed 
via TWR  
Time period 
(1 = 2000-02; 
2 = 2003-08) 
2 Jan-00 Sep-00 264 37 (14)   1 Stone [8] 
2 Jan-00 Sep-00 105 26 (24.8)   1 
Moreea [9] 2 NA NA 25 4 (16)   1 
Stoker [7] 2 NA NA 151 18 (11.9)   1 
Debnath [10] 1 Aug-00 Jul-01 237 21 (8.9) 96 21.9 1 
Walsh [11] 1 Aug-00 Oct-00 78 8 (10.3) 38 21.1 1 
Boulton-Jones [6] 2 NA NA 394 46 (11.7) 123  37.4 1 
Eccersley [12] 1 Jun-00 May-01 173 26 (15) 145 17.9 1 
Chaudri [13] 2 NA NA 243 15 (6.2)   1 
Flashman [14] 1 Jul-00 Jun-01 758 65 (8.6) 249 26.1 1 
Trickett [15] 1 Nov-00 Oct-01  30 147 20.4 1 
Barwick [16] 1 Jan-01 Aug-01 144 14 (9.7)   1 
Davies [17] 1 Nov-99 Oct-02 2294 257 (11.2) 635 40.5 1 
Glancy [18] 1 Aug-00 Nov-01 326 32 (9.8)   1 
Chohan [19] 1 Jul-00 Dec-01 462 64 (13.9) 195 32.8 1 
Maruthachalam [20] 1 Jan-03 Dec-03 188  19 (10.1)   2 
Shenderey [21] 2 Jan-03 Dec-03  41 142 28.9  2 
Sidhu [22] 2 Jan-03 Jun-03 122 13 (10.7) 49 26.5 2 
Maruthachalam [23] 2 Mar-04 Jun-05 96 9 (9.4)   2 
Barrett [24] 1 Jan-02 Dec-02  43 154 27.9  1 
Rao [25] 1 Jun-03 Dec-03 319 14 (4.4) 54 25.9 2 
Smith [26] 1 Jan-02 Dec-04 2748 174 (6.3) 478 36.4 2 
John [27] 1 NA NA  43 100 43  2 
Aljarabah [28] 2 Apr-06 Sep-06 217 22 (10.1)   2 
1 NA NA 222 14 (6.3) 88 15.9 2 Rai [29] 
1 NA NA 1000 100 (10) 400 25  2 
Shaw [30] 1 Sep-05 Sep-06 204 12 (5.9)   2 
Bevis [31] 1 Oct-02 Sep-04  97 193 50.2  2 
John [32] 1 Apr-04 Mar-05 534 60 (11.2) 175 34.3 2 
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Table 2. Data Extracted for Meta-Analysis Relating to Patients with UGC from 22 Studies. Entries are Listed Chronologically  
According to Publication Date. Where Data was not Present in the Article, the Corresponding Box(es) were Greyed Out 
Lead author Ref. Article type 
(1 = article; 
2 = abstract) 
Study start 
date 
(mmm-yy) 
Study end 
date 
(mmm-yy) 
N
o
 TWR 
referrals 
N
o
 cancers 
(%) 
Total N
o
 cancers 
diagnosed  
during the study 
period 
% cancers 
diagnosed 
via TWR  
Time period 
(1 = 2000-02; 
2 = 2003-08) 
Spencer [33] 2 NA NA 63 7 (11)   1 
Mahmood [34] 2 NA NA 45 2 (4.4)   1 
Stoker [7] 2 NA NA 112 7 (6.3)   1 
Lassman [35] 2 NA NA 79 12 (15.2)   1 
Loehry [36] 2 Apr-01 Sep-01 79 3 (3.8)   1 
Boulton-
Jones 
[6] 2 NA NA 280 27 (9.6) 76 35.5 1 
Subramanian [37] 2 Jul-00 Aug-01 199 11 (5.5)   1 
Warner [38] 2 NA NA 146 10 (6.8) 114 8.7 1 
Barbour [39] 2 Oct-01 Mar-02 172 17 (9.9) 35 48.6 1 
Aung [40] 2 Sep-00 Dec-01 307 29 (9.4) 105 27.6 1 
Reilly [41] 2 Aug-00 Jul-01 79 8 (10.1) 30 26.7 1 
Radbourne [42] 2 Jul-00 Dec-01 153 16 (10.5) 109 14.7 1 
Mohammed [43] 2 Nov-99 Dec-01  16 144  11.1  1 
1 Jul-00 Feb-02 1852 70 (3.8)   1 Kapoor [44] 
1 Mar-02 Feb-03 1785 52 (2.9)   1 
Spahos [45] 1 Sep-00 Aug-02 623 38 (6.1) 247 15.4 1 
Cairns [46] 2 Jan-02 Mar-04  55 100 55  1 
Ng [47] 2 Oct-03 Mar-04 125 8 (6.4) 53 15.1 2 
Carty [48] 2 Jan-01 Dec-01 191 4 (2.1) 16 25 1 
Moran [49] 2 Jan-03 Dec-03 356 18 (5) 124 14.5 2 
Dewar [50] 2 Jan-04 Dec-04 321 12 (3.7) 75  16 2 
2 Jan-02 Dec-02 157 6 (3.8) 57 10.5 1 
2 Jan-05 Dec-05 261 24 (9.2) 62 38.7 2 
Gera [51] 
2 Jan-04 Aug-04 175 16 (9.1) 31 51.6 2 
Irving [52] 2 Apr-07 Apr-08 295 34 (11.5) 53 64.2 2 
 
first stage study. Perhaps if the time periods had been more 
equal this decrease would not have occurred. 
 The remaining two studies with two-stage evaluations 
both showed marked increases in the UGC pick-up rate of 
the TWR [48, 51]. This may have been due to the significant 
time period that had elapsed between the two stages of the 
studies – approximately three years. Both studies also re-
ported a marked increase in the proportion of patients with 
UGCs being referred using the TWR compared with other 
routes (such as emergency or routine referrals). 
 The low GI cancer pick-up rate following a TWR referral 
suggests that the guidelines may not be effective. GPs may 
have inappropriately referred patients due to the incorrect 
interpretation or to the need to deliberately speed up diagno-
ses in low-risk patients where the routine waiting list was too 
long due to patient pressure or other demands on NHS endo-
scopy services. We also acknowledge that the symptoms 
exhibited by patients visiting their GP can be misinterpreted 
as potential cancer symptoms when they are, in fact, benign 
GI conditions such as reflux, dyspepsia or haemorrhoids. 
However, this review did not aim to collect the proportion of 
inappropriate referrals to the TWR by each study and the 
proportion of those who were later diagnosed with a GI can-
cer so we are unable to test this hypothesis using this data. 
 Perhaps it is the location of these cancers that has caused 
these differences? UGCs have a wide range of indicative 
symptoms which are also present in a number of benign con-
ditions such as reflux, dyspepsia and abdominal pain. This 
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would increase the number of TWR referrals and lower the 
proportion of patients later diagnosed with a UGC. The same 
is true of CRC, with bloody stools and haemorrhoids being 
as common in benign conditions.  
 When we consider the proportion of these cancers being 
diagnosed via the TWR compared with other referral routes 
such as emergency referrals, routine referrals, etc, we see 
that there has been relatively little change for CRC patients, 
whilst the proportion of UGC patients being diagnosed via 
the TWR has increased over time from 18.3% to 33.5%. This 
may be explained by the embarrassing nature of CRC means 
that many symptomatic patients do not present to their GPs 
until the latter stages [24], which tend to be too advanced to 
confidently predict a good outcome for the patient. UGCs do 
not have the same social stigma attached. Consequently, the 
GP has more opportunity to exercise the TWR referral in this 
case. Another explanation may be that emergency referrals 
would never see a GP to allow a TWR referral to be insti-
gated. Those articles quoting the proportion of GI cancer 
patients diagnosed via the A&E route state numbers ranging 
from 13.4% - 35.3% for CRCs [12, 14, 15, 17, 19, 21, 27, 
31, 32] and from 31% - 41% for UGCs [37, 39, 40]. 
 In more recent articles and abstracts, the proportion of 
newly diagnosed CRCs not identified by the TWR can be 
attributed in part to the English Bowel Cancer Screening 
Programme which was rolled out in April 2006. Men and 
women aged between 60-69 years were asked to submit fae-
cal occult blood tests (FOBTs) to their local screening unit. 
Any patients with positive FOBTs were referred for colono-
scopy or flexible sigmoidoscopy [53]. This programme may 
be identifying asymptomatic CRC patients who would not 
then present via TWR or emergency routes, thus explaining 
the lack of improvement in the proportion of CRC patients 
identified using the TWR. 
 The TWR has placed a significant burden on the re-
sources of most gastroenterology services in the NHS with 
little gain in identifying malignancies [54]. Most hospitals 
have a dedicated TWR referral list to ensure their Trust 
meets the strict two-week target. This should, in theory, have 
a negative impact on all other aspects of the service, al-
though no evidence of this has been found to date. Three 
studies reported a decline in the routine endoscopy waiting 
lists following the introduction of the TWR [11, 25, 45], 
possibly due to an increased awareness of the guidelines for 
patient referrals, the more efficient organisation of services 
or the introduction of nurse endoscopists to cope with in-
creased demand.  
 The effect of the TWR on long term survival remains 
unknown [11]. Many studies have reported no significant 
difference in the stage of the disease in CRC patients re-
ferred via the TWR compared with other referral routes [12, 
14, 19, 26, 31]. This finding was supported by a study by 
Kiran et al., who reported that there was no relation between 
the duration of CRC symptoms and the stage at presentation 
[55]. This means that those patients with advanced stages of 
CRC do not necessarily become symptomatic at a particular 
time, so the TWR does not necessarily improve the survival 
of CRC patients but does reportedly reduce the number of 
patients presenting as emergency cases [56]. Contrary to this, 
one study has shown that the TWR route has more CRC pa-
tients with Duke’s classification stage D (late stage) tumours 
than any other route (TWR = 14, outpatient clinics = 8, A&E 
= 5) [19].  
 When we compare the results of this review with the na-
tional cancer statistics for the UK published by Cancer Re-
search UK, we find that age-standardised (European) mortal-
ity rates for CRC have decreased in both males and females 
between 2000 and 2006 [57]. The same decrease was seen 
for gastric cancer [58]. However, mortality rates for oeso-
phageal cancer appear to have marginally decreased for fe-
males but have peaks and troughs with a marginal overall 
increase for males [59]. The decrease in CRC mortality can-
not obviously be explained by the TWR, given the low CRC 
pick-up rate and the relatively small increase in the propor-
tion of TWR-derived CRC diagnoses. However, the intro-
duction of screening may contribute to this statistic. We re-
ported a slight increase in UGC pick-up rates and a large 
increase in the proportion of UGCs being detected by the 
TWR. This may explain the decrease in mortality described 
by these statistics when we combine the trends for the mor-
tality rates for oesophageal and gastric cancers. 
 We feel that the TWR has had a positive impact on the 
NHS as it has raised the awareness of GPs and NHS staff to 
refer potential cancer patients in a timelier manner to expe-
dite their treatment and potentially improve their chances of 
survival, especially as this is a Government target. However, 
given the low cancer pick-up rates for both CRC and UGC, it 
is likely that the target assigned to the TWR (that the patient 
must be seen within 2 weeks on this system) has become 
more important than the reason for the referral, namely that 
the patients may have a cancer. We have no data on which 
patients were truly eligible for the TWR according to the 
guidelines as this data was not part of the remit of this re-
view but it is possible that 1) inappropriate referrals are di-
luting the impact of the TWR and lowering the cancer 
pickup rates and 2) the guidelines are not effective enough, 
possibly because they are not compulsory and can be over-
ridden by clinical judgement by the GP or because they are 
open to interpretation by the GP. 
 It may be that had further initiatives such as the Modern-
ising Endoscopy Services Programme [60], the Global Rat-
ing Scale [61] and the 18-week target [62] not been intro-
duced, we may have seen more resources diverted to NHS 
endoscopy services as they began to manage their TWR lists 
without detriment to the routine waiting lists. 
CONCLUSION  
 The TWR pick-up rates reported here suggest that the 
TWR is diagnosing a low proportion of patients with either 
CRCs or UGCs. An improved way of identifying sympto-
matic patients as they present to their GP is required, along 
with a more rigorous system for validating referral guide-
lines to reduce the number of inappropriate referrals within 
the system. 
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